SALICYLIC ACID

Ukraine

The drug is used for infectious skin lesions, particularly for common acne and pyoderma.

Brand name SALICYLIC ACID
Dosage form solution, alcoholic, for external use
Active substance / Dosage
Prescription type over-the-counter (OTC)
ATC code
Registration number UA/3506/01/01
SALICYLIC ACID solution, alcoholic, for external use

Frequently asked questions

How should salicylic acid be used correctly?

The product should be applied externally to the affected areas of the skin, by applying or rubbing them with a cotton swab soaked in the solution, 2–3 times a day. The duration of the course is determined by a physician.

What are the possible side effects of salicylic acid?

Skin irritation, dryness, peeling, itching, or allergic reactions are possible. With prolonged use, absorption into the blood is possible, which may cause tinnitus, dizziness, nausea, vomiting, stomach pain, or rapid breathing.

Who should not use this drug?

The product should not be used in cases of increased individual sensitivity to it, nor in children under 12 years of age. The solution should not be applied to mucous membranes or into the eyes.

Can this product be combined with other medicines?

Local application should not be combined with the oral intake of preparations containing acetylsalicylic acid or other non-steroidal anti-inflammatory drugs. It should also not be used together with benzoyl peroxide or topical retinoids. The drug may enhance the effect of some other medicines, so it is important to inform your doctor.

Can the drug be used by pregnant or breastfeeding women?

This is only possible in cases where the expected benefit to the mother outweighs the potential risk to the child or fetus.

Instructions for use

INSTRUCTIONS for medical use of the medicinal product SALICYLIC ACID (SALICYLIC ACID)

Composition:

Active ingredient: salicylic acid;

100 ml of solution contain salicylic acid - 1 g;

Excipient: ethanol 70%.

Pharmaceutical form. Topical solution, alcoholic.

Main physicochemical properties: clear, colorless liquid.

Pharmaco-therapeutic group. Dermatological agents. ATC code D01AE12.

Pharmacological properties.

An antiseptic agent. When applied topically, exerts antimicrobial, irritant, and counterirritant effects.

Clinical characteristics.

Indications.

Used for infectious skin lesions: common acne, pyoderma.

Contraindications.

Increased individual sensitivity to the drug.

Safety precautions.

Avoid contact of the drug with eyes; do not apply to mucous membranes.

Do not violate the application instructions for the medicinal product — this may harm your health.

The drug must not be used after the expiry date stated on the packaging.

Interaction with other medicinal products and other types of interactions.

Topical salicylic acid should not be combined with oral administration of drugs containing acetylsalicylic acid and other nonsteroidal anti-inflammatory agents. Do not use concurrently with benzoyl peroxide and topical retinoids.

Salicylic acid may enhance skin permeability to other topical medicinal products, thereby increasing their systemic absorption. In addition, salicylic acid may potentiate the adverse effects of methotrexate and the hypoglycemic effect of oral antidiabetic drugs — sulfonylurea derivatives.

If you are taking any other medicinal products, you must inform your doctor.

Special instructions.

Do not apply the medicinal product to large areas of skin.

Use during pregnancy or breastfeeding.

During pregnancy or breastfeeding, the drug should be used only when the expected benefit to the mother outweighs the potential risk to the fetus or infant.

Ability to influence reaction rate while driving or operating machinery.

Does not affect.

Method of administration and dosage.

Apply externally by wiping or rubbing the affected areas of skin with a cotton swab soaked in the preparation, 2─3 times daily.

The duration of treatment is determined by a physician depending on the course and severity of the disease.

Children.

Do not use in children under 12 years of age.

Overdose .

When large doses are applied, keratolytic effect and allergic reactions may be intensified. In such a case, the preparation should be washed off with water and medical advice should be sought. Symptomatic therapy.

Side effects.

Possible skin reactions: dryness, peeling, irritation, contact dermatitis, allergic manifestations (urticaria, pruritus), which require discontinuation of the drug.

With prolonged use, systemic absorption of the drug may occur, leading to side effects typical of salicylates: tinnitus, dizziness, epigastric pain, nausea, vomiting, acidosis, and rapid breathing.

If any adverse reactions occur, consult a physician immediately!

Shelf life. 3 years.

Storage conditions.

Store at a temperature not exceeding 25 °C. Keep out of reach of children.

Packaging. 40 ml or 25 ml in bottles.

Dispensing category. Over-the-counter (without prescription).

Manufacturer.

LLC "DKP "Pharmaceutical Factory".

Manufacturer's location and address of business activity.

4, Korolova St., Stanishivka village, Zhytomyr district, Zhytomyr region, 12430, Ukraine.

Similar drugs

Brand name Dosage form Active substance / Dosage Manufacturer
SALICYLIC ACID solution, alcoholic, for external use
salicylic acid · 20 mg/ml
DKP "Pharmaceutical Factory" LLC
SALICYLIC ACID solution, alcoholic, for external use
salicylic acid · 1 g/100 ml
LLC "UKRSPEKSFARM"
SALICYLIC ACID solution, alcoholic, for external use
salicylic acid · 1 g/100 ml
PJSC Pharmaceutical Factory "Viola"
SALICYLIC ACID solution, alcoholic, for external use Ternofarm LLC
SALICYLIC ACID 1 % solution, alcoholic, for external use
salicylic acid · 1 g/100 ml
Farmak Cherkasy LLC
SALICYLIC ACID ALCOHOLIC SOLUTION solution, alcoholic, for external use PJSC "Fitofarm"
SALITSISKA-VISHFA solution, alcoholic, for external use
salicylic acid · 1 g/100 ml
DKP "Pharmaceutical Factory" LLC

The original data is available in the language of the country of manufacture.

Data source: State Register of Medicinal Products of Ukraine

Data last verified: August 13, 2026